Last reviewed · How we verify
Mycophenolate mofetil, adjusted dose
Mycophenolate mofetil, adjusted dose is a Small molecule drug developed by Hoffmann-La Roche. It is currently FDA-approved. Also known as: CellCept.
At a glance
| Generic name | Mycophenolate mofetil, adjusted dose |
|---|---|
| Also known as | CellCept |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (PHASE2)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (PHASE2)
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (PHASE1, PHASE2)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate mofetil, adjusted dose CI brief — competitive landscape report
- Mycophenolate mofetil, adjusted dose updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Mycophenolate mofetil, adjusted dose
What is Mycophenolate mofetil, adjusted dose?
Mycophenolate mofetil, adjusted dose is a Small molecule drug developed by Hoffmann-La Roche.
Who makes Mycophenolate mofetil, adjusted dose?
Mycophenolate mofetil, adjusted dose is developed and marketed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).
Is Mycophenolate mofetil, adjusted dose also known as anything else?
Mycophenolate mofetil, adjusted dose is also known as CellCept.
What development phase is Mycophenolate mofetil, adjusted dose in?
Mycophenolate mofetil, adjusted dose is FDA-approved (marketed).
Related
- Manufacturer: Hoffmann-La Roche — full pipeline
- Also known as: CellCept
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing